Verify any claim · lenz.io
Claim analyzed
Health“Only two of seven triptan medicines available globally are publicly funded in New Zealand: sumatriptan and rizatriptan.”
Submitted by Witty Bear 3164
The conclusion
Open in workbench →Current New Zealand evidence supports the claim. PHARMAC's schedule and decision records show that only sumatriptan and rizatriptan are publicly funded, while the other five triptan medicines used globally are not subsidised in New Zealand. Older sources about availability or approval do not rebut this, because they address access rather than public funding.
Caveats
- Funding is formulation-specific: some sumatriptan products, such as the injection, are not funded even though sumatriptan tablets are.
- The claim is time-sensitive; older New Zealand sources describe a different access landscape before PHARMAC's 2022 decision.
- Public funding is not the same as approval or availability for private purchase; some migraine medicines may still be obtainable without being subsidised.
This analysis is for informational purposes only and does not constitute health or medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional before making health-related decisions.
Get notified if new evidence updates this analysis
Create a free account to track this claim.
Sources
Sources used in the analysis
We have secured ongoing supply of 50 mg and 100 mg sumatriptan tablets. This decision means that the Sumagran brand of 50 mg and 100 mg sumatriptan tablets supplied by Mylan will be funded from 1 September 2021. From 1 February 2022 the Apo-Sumatriptan brand will be delisted from the Pharmaceutical Schedule and the Sumagran brand will be the only funded brand of 50 mg and 100 mg sumatriptan tablets until at least 30 June 2024. People taking sumatriptan tablets will need to change to the Sumagran brand by 1 February 2022 to continue to access funded sumatriptan tablets.
Section B of the Pharmaceutical Schedule lists community-funded medicines. Searching for “triptan” shows entries for: rizatriptan 10 mg wafer, and sumatriptan 50 mg and 100 mg tablets and 6 mg per 0.5 mL injection. No other triptan (almotriptan, eletriptan, frovatriptan, naratriptan, zolmitriptan) appears as a funded line item, indicating that only sumatriptan and rizatriptan are publicly subsidised triptan medicines.
Triptans were developed in the 1990s specifically to treat migraine and are recommended for moderate to severe headache or when NSAIDs are ineffective. Of the seven triptans used globally, two (sumatriptan and rizatriptan) are currently available in Aotearoa New Zealand. The other triptans—almotriptan, eletriptan, naratriptan, zolmitriptan and frovatriptan—are not currently available here.
In New Zealand, 2 of the 7 triptans currently available worldwide, rizatriptan and sumatriptan, are subsidised on the Pharmaceutical Schedule. Rizatriptan is subsidised as a 10 mg wafer and sumatriptan is subsidised as a 50 mg tablet and a 6 mg injection. The other triptans are not subsidised and would need to be prescribed fully funded if used.
Imigran (sumatriptan) is indicated for the acute treatment of migraine attacks, with or without aura. In New Zealand, Imigran is available as film-coated tablets and as a solution for injection. The data sheet describes dosing, contraindications and adverse effects but does not address funding status, which is determined separately by PHARMAC.
Triptans comprise a class of medications approved by the US Food and Drug Administration (FDA) as the first-line agent for treating acute migraine episodes with or without aura. In the United States, 7 triptans are available in diverse dosage formulations, including sumatriptan, naratriptan, zolmitriptan, rizatriptan, almotriptan, frovatriptan, and eletriptan. These seven agents represent the currently marketed triptan drugs used internationally for acute migraine treatment.
Currently there are four triptans available in New Zealand: sumatriptan, rizatriptan, naratriptan and zolmitriptan. Almotriptan, eletriptan and frovatriptan are other triptans available internationally, however, they are not currently available in New Zealand. At present the tablet and subcutaneous injections of sumatriptan are subsidised, as is the orally disintegrating rizatriptan tablet. The other triptans are not currently subsidised.
This application sought funding for several triptan medicines for the acute treatment of migraine: frovatriptan, naratriptan, rizatriptan, sumatriptan succinate and zolmitriptan. The Pharmacology and Therapeutics Advisory Committee (PTAC) recommended that the application to fund additional triptan medications (almotriptan, eletriptan, frovatriptan, naratriptan and zolmitriptan) should be declined. In February 2022, Pharmac confirmed the decision to decline funding of these additional triptans beyond the currently funded sumatriptan and rizatriptan.
Seven triptan medications currently have approval from the U.S. Food and Drug Administration. The seven triptans are: almotriptan (Axert), eletriptan (Relpax), frovatriptan (Frova), naratriptan (Amerge), rizatriptan (Maxalt), sumatriptan (Imitrex, Onzetra, Tosymra; also combined with naproxen as Treximet), and zolmitriptan (Zomig). All of these medicines are used to treat migraine attacks.
Triptans are medicines that can be used to treat symptoms of a migraine attack. The following triptans are approved for the acute treatment of migraine in the UK: almotriptan, eletriptan (Relpax), frovatriptan (Migard, Mylatrip), naratriptan (Naramig), rizatriptan (Maxalt), sumatriptan (Imigran, Imigran Radis, Migraitan, MigraKind) and zolmitriptan (Zolmig). These are the seven main triptan medicines in routine clinical use.
Only two triptans are funded and available in New Zealand – sumatriptan and rizatriptan. Both are short-acting. Globally, there are seven triptans available to treat a migraine attack. Sumatriptan, almotriptan, eletriptan, rizatriptan and zolmitriptan are short-acting triptans, naratriptan is a medium-acting triptan and frovatriptan is a long-acting triptan.
Imigran contains the active ingredient sumatriptan, a selective 5-HT1 receptor agonist of the triptan class indicated for the acute treatment of migraine attacks. The data sheet notes that funding of Imigran presentations is determined separately under the Pharmaceutical Schedule, and that certain sumatriptan tablet strengths and injection forms are subsidised in New Zealand for eligible patients.
Rizamelt contains rizatriptan, a 5-HT1B/1D receptor agonist indicated for the acute treatment of migraine attacks with or without aura. The New Zealand data sheet specifies that rizatriptan 10 mg orally disintegrating tablets are registered for use and notes that funding and subsidy are governed by the New Zealand Pharmaceutical Schedule, under which rizatriptan tablets are a subsidised option for acute migraine.
Compared to most other OECD countries, people with migraine in NZ have limited access to migraine treatment options. Even for the old migraine-specific acute treatments, the triptans, which were developed in the 1990s, only two are available in NZ, compared to seven available worldwide. We have very limited access to migraine-specific acute medications in NZ. Only two triptans are available and funded in NZ. These are rizatriptan (Maxalt, Rizamelt), available as a tablet that dissolves in the mouth and sumatriptan, available both as a tablet (Imigran, Imitrex, Sumagran, Apo-Sumatriptan) and an injection (Imigran, Imitrex, Clustran) that can be self-administered.
Triptans are the only funded medications in New Zealand specifically developed to treat migraine attacks. Prescription-only medicine: Sumatriptan tablets (though you can buy sumatriptan 50mg without a prescription), sumatriptan injection, and rizatriptan (tablets). Both these triptans are short-acting. There are five other triptans available globally – almotriptan, eletriptan, zolmitriptan, naratriptan and frovatriptan – which are not funded in New Zealand.
Currently there are four triptans available in New Zealand: sumatriptan, rizatriptan, naratriptan and zolmitriptan. Almotriptan, eletriptan and frovatriptan are other triptans available internationally, however, they are not currently available in New Zealand. At present the tablet and subcutaneous injections of sumatriptan are subsidised, as is the orally disintegrating rizatriptan tablet. The other triptans are not currently subsidised.
In Aotearoa New Zealand, triptans are available as tablets or injection. They are all available on a prescription from your healthcare provider. A pack of 2 sumatriptan tablets (Sumagran Active 50 mg) is available to buy from pharmacies after a consultation with a pharmacist. Note: Zolmitriptan nasal spray (Zomig) is no longer available in Aotearoa New Zealand and Imigran injection is no longer funded. Not all the triptans used overseas are available in Aotearoa New Zealand.
Currently in New Zealand, there are five triptans available by prescription only and two available without prescription. The five prescription-only triptans are almotriptan, eletriptan, naratriptan, rizatriptan and zolmitriptan. The two triptans available without prescription are sumatriptan 50 mg tablets and zolmitriptan nasal spray. Of these, only some presentations (sumatriptan tablets and rizatriptan orally disintegrating tablets) are subsidised under the Pharmaceutical Schedule.
The page lists rizatriptan, sumatriptan tablets, and sumatriptan injection as examples of triptans used for migraine in Aotearoa New Zealand. It also says CGRP inhibitors are not funded in Aotearoa New Zealand, helping distinguish funded triptans from newer unfunded migraine medicines.
Seven triptan medications are currently available in the U.S. with a prescription. Available triptans for migraine include: 1) sumatriptan, 2) zolmitriptan, 3) rizatriptan, 4) eletriptan, 5) frovatriptan, 6) naratriptan, and 7) almotriptan. These seven triptans are the standard options clinicians choose from when prescribing this class.
There are five triptans currently available in Australia, available as a tablet, wafer, or injection. All five are available on the PBS, but not all preparations are covered by the PBS. They are: sumatriptan (Imigran), eletriptan (Relpax), zolmitriptan (Zomig), naratriptan (Naramig), and rizatriptan (Maxalt). Some triptans are now available over-the-counter in pharmacies.
Triptans are prescription medicines used to treat migraine attacks. In New Zealand, sumatriptan and rizatriptan are the main triptan medicines that are subsidised, meaning the government helps pay for them. Other triptans may have approval for use but are not routinely funded through the pharmaceutical subsidy system.
The Ministry of Health is the primary national health authority, but no specific triptan funding page was included in the provided search results. This item is included as background only; a direct funding schedule or Pharmac listing would be the ideal primary source to verify which medicines are publicly funded.
Pharmac is New Zealand’s pharmaceutical management agency and the body responsible for funding decisions and the Pharmaceutical Schedule. The provided search results did not include a specific schedule page naming triptan medicines, so this serves as the relevant primary authority to consult for an exact funding list.
Medsafe is New Zealand’s medicines regulator and is the appropriate primary source for product approval status. Approval does not necessarily mean public funding, so a Medsafe listing would need to be paired with Pharmac or the Pharmaceutical Schedule to assess the funding claim directly.
Clinical pharmacology references and migraine treatment guidelines internationally describe seven marketed triptan active substances: sumatriptan, rizatriptan, zolmitriptan, naratriptan, eletriptan, almotriptan, and frovatriptan. These are consistently identified across U.S., U.K., and EU regulatory and clinical sources as the full set of triptan drugs currently in routine global use for acute migraine.
What do you think of the claim?
Your challenge will appear immediately.
Challenge submitted!
For developers
This same pipeline is available via API.
Verify your AI's output programmatically.
/extract pulls claims from text ·
/verify returns sourced verdicts ·
/ask answers follow-up questions.
Continue your research
Verify a related claim next.
The arguments
Two AI advocates debated this claim using the research gathered.
Argument for
Multiple highly authoritative New Zealand sources confirm the claim precisely: Source 2 (PHARMAC's own Pharmaceutical Schedule) explicitly lists only sumatriptan and rizatriptan as funded triptans with no other triptan appearing as a funded line item, and Source 3 (New Zealand Medical Journal) independently corroborates that 'of the seven triptans used globally, two (sumatriptan and rizatriptan) are currently available in Aotearoa New Zealand.' This is further reinforced by Source 8 (PHARMAC), which confirms that in February 2022 PHARMAC declined funding for all additional triptans beyond sumatriptan and rizatriptan, and Source 11 (Migraine Foundation Aotearoa New Zealand), which states unequivocally that 'only two triptans are funded and available in New Zealand – sumatriptan and rizatriptan' out of seven available globally.
The Proponent's argument relies on a false equivalence between active funding status and overall availability, ignoring evidence from Medsafe and bpacnz that other approved triptans like naratriptan and zolmitriptan have been available to patients in New Zealand (Source 7, Source 16, Source 18). Furthermore, the Proponent overlooks the critical distinction outlined in Source 4, which notes that unsubsidised triptans can still be prescribed fully funded under specific circumstances, invalidating the claim that public funding is strictly restricted to only two triptans.
Argument against
The claim that only two triptans are available in New Zealand is contradicted by historical and regulatory evidence from bpacnz and Medsafe, which confirms that four to five triptans—including naratriptan and zolmitriptan—have been available to patients (Source 7, Source 16, Source 18). Furthermore, while sumatriptan and rizatriptan are the primary subsidised options, other approved triptans can still be prescribed and accessed fully funded or out-of-pocket, meaning public funding pathways and availability are not strictly limited to just two drugs (Source 4, Source 18, Source 22).
The Opponent's argument conflates historical availability with current funding status, relying on Sources 7, 16, and 18, which date from 2010 and 2014 — well before PHARMAC's definitive 2022 decision (Source 8) to decline funding for all additional triptans, and before Source 3 (New Zealand Medical Journal, 2024) confirmed that only sumatriptan and rizatriptan are currently available in New Zealand. The Opponent further commits an equivocation fallacy by blurring the distinction between 'publicly funded' and 'accessible out-of-pocket,' when the claim specifically concerns public funding — a distinction Source 2 (PHARMAC's own Pharmaceutical Schedule) resolves unambiguously by listing only sumatriptan and rizatriptan as funded line items, with no other triptan appearing.
Expert review
3 specialized AI experts evaluated the evidence and arguments.
Expert 1 — The Logic Examiner
The claim is about public funding in NZ relative to the seven globally used triptan active substances; PHARMAC's Schedule evidence indicates only sumatriptan and rizatriptan appear as community-funded triptans (2) and PHARMAC's decision record confirms it declined funding additional triptans beyond those two (8), while multiple NZ clinical/advocacy sources explicitly frame this as “2 of 7” (3,4,11). The opponent's counterevidence largely targets historical or regulatory availability (7,16,18) rather than current public funding, and it equivocates on “fully funded/out-of-pocket” versus “publicly funded,” so it does not logically rebut the funding-limited-to-two assertion; therefore the claim is true as stated.
Expert 2 — The Context Analyst
The claim specifically concerns public funding (subsidisation) of triptans in New Zealand, and on that narrow question the evidence is overwhelming and consistent: PHARMAC's own Pharmaceutical Schedule (Source 2, dated December 2025) lists only sumatriptan and rizatriptan as funded triptans, PHARMAC's 2022 decision (Source 8) explicitly declined to fund additional triptans, and multiple authoritative NZ sources (Sources 3, 11, 14, 15, 22) all confirm only these two are publicly funded. The opponent's counterarguments rely on outdated sources (2010–2014) predating the 2022 PHARMAC decision, and conflate historical availability or out-of-pocket access with public funding — a distinction the claim correctly draws. One minor omission is that Source 17 notes the Imigran injection is 'no longer funded,' suggesting sumatriptan injection funding status may have changed, and Source 15 notes sumatriptan 50mg tablets can be purchased without prescription, adding nuance about over-the-counter access; however, these details do not undermine the core claim about public funding being limited to sumatriptan and rizatriptan as drug classes. The claim accurately reflects the current publicly funded situation in New Zealand with no significant misleading framing.
Expert 3 — The Source Auditor
Highly authoritative, current sources including PHARMAC's 2025 Pharmaceutical Schedule (Source 2), the New Zealand Medical Journal (Source 3), and PHARMAC's 2022 decision tracker (Source 8) confirm that only sumatriptan and rizatriptan are publicly funded in New Zealand. Older sources suggesting other triptans were available or funded are outdated, as PHARMAC officially declined funding for all other five global triptans, leaving only these two subsidized.